Gary N. Schwartz

4.9k total citations
89 papers, 3.7k citations indexed

About

Gary N. Schwartz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Gary N. Schwartz has authored 89 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 30 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Gary N. Schwartz's work include Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (9 papers). Gary N. Schwartz is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (9 papers). Gary N. Schwartz collaborates with scholars based in United States, Spain and Italy. Gary N. Schwartz's co-authors include Wendy A. Wells, Peter A. Kaufman, Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Charlotte T. Furstenberg, Brett Hanscom, Lorenzo F. Sempere, Lois Ayash and Catherine V. Heath and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Gastroenterology.

In The Last Decade

Gary N. Schwartz

87 papers receiving 3.6k citations

Peers

Countries citing papers authored by Gary N. Schwartz

Since Specialization

Citations

This map shows the geographic impact of Gary N. Schwartz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary N. Schwartz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary N. Schwartz more than expected).

Fields of papers citing papers by Gary N. Schwartz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary N. Schwartz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary N. Schwartz. The network helps show where Gary N. Schwartz may publish in the future.

Co-authorship network of co-authors of Gary N. Schwartz

This figure shows the co-authorship network connecting the top 25 collaborators of Gary N. Schwartz. A scholar is included among the top collaborators of Gary N. Schwartz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary N. Schwartz. Gary N. Schwartz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Estrogen Therapy Induces Receptor-Dependent DNA Damage Enhanced by PARP Inhibition in ER+ Breast Cancer 2023 ·Clinical Cancer Research ·Nicole A. Traphagen, Gary N. Schwartz, (unknown), (unknown), (unknown), (unknown), Jonathan D. Marotti, (unknown), (unknown), (unknown), (unknown), Eugene Demidenko, (unknown), Yaron Mosesson, Shannon M. Soucy, Fred Kolling, Todd W. Miller	8
2	Near-Infrared Spectral Tomography for Predicting Residual Cancer Burden during Early-Stage Neoadjuvant Chemotherapy for Breast Cancer 2023 ·Clinical Cancer Research ·Xu Cao, Kristen E. Muller, Mary D. Chamberlin, Jiang Gui, Peter A. Kaufman, Gary N. Schwartz, Roberta M. diFlorio‐Alexander, Brian W. Pogue, Keith D. Paulsen, Shudong Jiang	2
3	Alternating 17β-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer 2023 ·Clinical Cancer Research ·Gary N. Schwartz, Peter A. Kaufman, Karthik V. Giridhar, Jonathan D. Marotti, Mary D. Chamberlin, Bradley A. Arrick, Grace Makari‐Judson, Matthew P. Goetz, Shannon M. Soucy, Fred Kolling, Eugene Demidenko, Todd W. Miller	3
4	Plasma DNA as a “liquid biopsy” incompletely complements tumor biopsy for identification of mutations in a case series of four patients with oligometastatic breast cancer 2020 ·Breast Cancer Research and Treatment ·Mary D. Chamberlin, (unknown), Kevin Shee, (unknown), Jonathan D. Marotti, Wendy A. Wells, Heidi W. Trask, Fred Kolling, (unknown), Peter A. Kaufman, Gary N. Schwartz, John M. Gemery, Nancy J. McNulty, Michael J. Tsapakos, Richard J. Barth, Bradley A. Arrick, Jiang Gui, Todd W. Miller	1
5	Recurrent dermatofibrosarcoma protuberans treated with neoadjuvant imatinib mesylate followed by Mohs micrographic surgery 2017 ·JAAD Case Reports ·Natalia M. Fontecilla, (unknown), Larisa J. Geskin, Faramarz H. Samie, George Niedt, Thomas A. Imahiyerobo, Gary N. Schwartz, (unknown), Jesse M. Lewin	5
6	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy 2015 ·Clinical Cancer Research ·William J. Gradishar, Denise A. Yardley, Rachel M. Layman, Joseph A. Sparano, Ellen Chuang, Donald W. Northfelt, Gary N. Schwartz, Hagop Youssoufian, Shande Tang, Ruslan D. Novosiadly, Amélie Forest, Tuan S. Nguyen, Jan Cosaert, Dmitri Grebennik, Paul Haluska	54
7	Patients' Understanding of How Genotype Variation Affects Benefits of Tamoxifen Therapy for Breast Cancer 2014 ·Public Health Genomics ·(unknown), Jessica T. DeFrank, (unknown), Joseph G. Ibrahim, Christine M. Walko, Peter Rubin, (unknown), Susan Moore, (unknown), (unknown), (unknown), Gary N. Schwartz, (unknown), Howard L. McLeod, Lisa A. Carey, William P. Irvin	6
8	Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: the impact of APOE and smoking 2014 ·PMC ·Tim A. Ahles, Yuelin Li, Brenna C. McDonald, Gary N. Schwartz, Peter A. Kaufman, Gregory J. Tsongalis, Jason H. Moore, Andrew J. Saykin	2
9	Longitudinal Assessment of Cognitive Changes Associated With Adjuvant Treatment for Breast Cancer: Impact of Age and Cognitive Reserve 2010 ·Journal of Clinical Oncology ·Tim A. Ahles, Andrew J. Saykin, Brenna C. McDonald, Yuelin Li, Charlotte T. Furstenberg, Brett Hanscom, (unknown), Gary N. Schwartz, Peter A. Kaufman	390
10	Altered MicroRNA Expression Confined to Specific Epithelial Cell Subpopulations in Breast Cancer 2007 ·Cancer Research ·Lorenzo F. Sempere, Mette Christensen, Asli Silahtaroglu, Mads Bak, Catherine V. Heath, Gary N. Schwartz, Wendy A. Wells, Sakari Kauppinen, Charles N. Cole	473
11	Quality of life among patients with Stage II and III breast carcinoma randomized to receive high‐dose chemotherapy with autologous bone marrow support or intermediate‐dose chemotherapy 2005 ·Cancer ·Jeffrey Peppercorn, James E. Herndon, Alice B. Kornblith, William P. Peters, Tim A. Ahles, James J. Vredenburgh, Gary N. Schwartz, Elizabeth J. Shpall, David D. Hurd, Jimmie C. Holland, Eric P. Winer, (unknown)	26
12	Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy 2003 ·Cancer Chemotherapy and Pharmacology ·Lakshmi Pendyala, Gary N. Schwartz, Patrick F. Smith, Joseph Zdanowicz, Michael P. Murphy, Frederick H. Hausheer	12
13	Is MUGA Scan Necessary in Patients With Low-Risk Breast Cancer Before Doxorubicin-Based Adjuvant Therapy? 2001 ·American Journal of Clinical Oncology ·Michael S. Sabel, Ellis Levine, Thelma C. Hurd, Gary N. Schwartz, Robert Zielinski, D. Höhn, Stephen B. Edge	28
14	Surgery versus radiation therapy as single‐modality treatment of tonsillar fossa carcinoma: The roswell park cancer institute experience (1971–1991) 1998 ·The Laryngoscope ·Wesley L. Hicks, Moni Abraham Kuriakose, (unknown), James B. Orner, Gary N. Schwartz, (unknown), Craig Donaldson, (unknown), Vahram Y. Bakamjian	49
15	Kinetics of peripheral blood mononuclear cell mobilization with chemotherapy and/or granulocyte‐colony‐stimulating factor: implications for yield of hematopoietic progenitor cell collections 1996 ·Transfusion ·Iain J. Webb, (unknown), AD Elias, Lois Ayash, C Wheeler, Gary N. Schwartz, George D. Demetri, K C Anderson	18
16	High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity 1995 ·Cancer Chemotherapy and Pharmacology ·Joel E. Wright, Anthony Elias, (unknown), Sylvia A. Holden, Janet Andersen, Catherine Wheeler, Gary N. Schwartz, Karen H. Antman, A. Rosowsky, (unknown), Lois Ayash	24
17	High-Dose Chemotherapy with Autologous Stem Cell Support for Breast Cancer: A Review of the Dana-Farber Cancer Institute/Beth Israel Hospital Experience 1993 ·Journal of Hematotherapy ·Lois Ayash, Anthony Elias, Catherine Wheeler, Isidore Tepler, Gary N. Schwartz, Lowell E. Schnipper, Emil Frei, Karen H. Antman	3
18	The Use of G-CSF or GM-CSF Mobilized Peripheral Blood Progenitor Cells (PBPC) Alone or to Augment Marrow as Hematologic Support of Single or Multiple Cycle High-Dose Chemotherapy 1993 ·Journal of Hematotherapy ·Anthony Elias, Lois Ayash, I Tepler, C Wheeler, Gary N. Schwartz, Rosemary Mazanet, Lowell E. Schnipper, E Frei, Karen H. Antman	8
19	High-Dose Combined Alkylating Agent Therapy With Autologous Stem Cell Support and Chest Radiotherapy for Limited Small-Cell Lung Cancer 1993 ·CHEST Journal ·Anthony Elias, Lois Ayash, Arthur T. Skarin, C Wheeler, Gary N. Schwartz, Rosemary Mazanet, Isidore Tepler, Lowell E. Schnipper, E Frei, Karen H. Antman	8
20	Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine 1993 ·Cancer Chemotherapy and Pharmacology ·Gary N. Schwartz, Beverly A. Teicher, Joseph P. Eder, Timothy Korbut, (unknown), (unknown), (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact